Diabetic foot ulcer(Redirected from Neuropathic ulcer)
|Diabetic foot ulcer|
|Neuropathic diabetic foot ulcer|
Wound healing is an innate mechanism of action that works reliably most of the time. A key feature of wound healing is stepwise repair of lost extracellular matrix (ECM) that forms the largest component of the dermal skin layer. But in some cases, certain disorders or physiological insult disturbs the wound healing process. Diabetes mellitus is one such metabolic disorder that impedes the normal steps of the wound healing process. Many studies show a prolonged inflammatory phase in diabetic wounds, which causes a delay in the formation of mature granulation tissue and a parallel reduction in wound tensile strength.
Treatment of diabetic foot ulcers should include: blood sugar control, removal of dead tissue from the wound, wound dressings, and removing pressure from the wound through techniques such as total contact casting.And also it poor circulation on the feet.  Surgery in some cases may improve outcomes. Hyperbaric oxygen therapy may also help but is expensive.
Doctors also use the Wagner Grades to describe the severity of an ulcer. The purpose of the Wagner Grades is to allow specialists to better monitor and treat diabetic foot ulcers. This grading system classifies Diabetic foot ulcers using numbers, from 0 to 5.
Wagner Grades 0 through 5 are as follows:
- 0. You do not yet have a Diabetic foot ulcer, but are at high risk to develop one.
- 1. You have a surface ulcer that involves full skin thickness, but does not yet involve the underlying tissues.
- 2. You have a deep ulcer that penetrates past the surface, down to the ligaments and muscle. There is no abscess or bone involved yet.
- 3. You have a deep ulcer with inflammation of subcutaneous connective tissue or an abscess. This can include infections in the muscle, tendon, joint, and/or bone.
- 4. The tissue around the area of your ulcer (limited to the toes and forefoot) has began to decay. This is condition is called gangrene.
- 5. Gangrene has spread from the localized area of the ulcer to become extensive. This involves the whole foot.
Risk factors implicated in the development of diabetic foot ulcers are infection, older age, diabetic neuropathy, peripheral vascular disease, cigarette smoking, poor glycemic control, previous foot ulcerations or amputations, and ischemia of small and large blood vessels. Prior history of foot disease, foot deformities that produce abnormally high forces of pressure, renal failure, oedema, impaired ability to look after personal care (e.g. visual impairment) are further risk factors for diabetic foot ulcer.
People with diabetes often develop diabetic neuropathy due to several metabolic and neurovascular factors. Peripheral neuropathy causes loss of pain or feeling in the toes, feet, legs and arms due to distal nerve damage and low blood flow. Blisters and sores appear on numb areas of the feet and legs such as metatarso-phalangeal joints, heel region and as a result pressure or injury goes unnoticed and eventually become portal of entry for bacteria and infection.
Extra cellular matrix (or "ECM") is the external structural framework that cells attach to in multicellular organisms. The dermis lies below the epidermis, and these two layers are collectively known as the skin. Dermal skin is primarily a combination of fibroblasts growing in this matrix. The specific species of ECM of connective tissues often differ chemically, but collagen generally forms the bulk of the structure.
Through the interaction of cell with its extracellular matrix (transmitted through the anchoring molecules classed as integrins) there forms a continuous association between cell interior, cell membrane and extracellular matrix components that help drive various cellular events in a regulated fashion. Wound healing is a localized event involving the reaction of cells to the damage sustained.
The cells break down damaged ECM and replace it, generally increasing in number to react to the harm. The process is activated, though perhaps not exclusively, by cells responding to fragments of damaged ECM, and the repairs are made by reassembling the matrix by cells growing on and through it. Because of this extracellular matrix is often considered as a 'conductor of the wound healing symphony'. In the Inflammatory phase, neutrophils and macrophages recruit and activate fibroblasts which in subsequent granulation phase migrate into the wound, laying down new collagen of the subtypes I and III.
In the initial events of wound healing, collagen III predominates in the granulation tissue which later on in remodeling phase gets replaced by collagen I giving additional tensile strength to the healing tissue. It is evident from the known collagen assembly that the tensile strength is basically due to fibrillar arrangement of collagen molecules, which self-assemble into microfibrils in a longitudinal as well as lateral manner producing extra strength and stability to the collagen assembly. Metabolically altered collagen is known to be highly inflexible and prone to break down, particularly over pressure areas. Fibronectin is the major glycoprotein secreted by fibroblasts during initial synthesis of extracellular matrix proteins. It serves important functions, being a chemo-attractant for macrophages, fibroblasts and endothelial cells.
Basement membrane that separates epidermis from the dermal layer and endothelial basement membrane mainly contain collagen IV that forms a sheet and binds to other extra cellular matrix molecules like laminin and proteoglycans. In addition to collagen IV, epidermal and endothelial basement membrane also contain laminin, perlecan and nidogen. Hyaluronic acid, a pure glycosaminoglycan component is found in high amounts in damaged or growing tissues. It stimulates cytokine production by macrophages and thus promotes angiogenesis. In normal skin chondroitin sulfate proteoglycan is mainly found in the basement membrane but in healing wounds they are up regulated throughout the granulation tissue especially during second week of wound repair, when they provide a temporary matrix with highly hydrative capacity. Binding of growth factors is clearly an important role of perlecan in wound healing and angiogenesis. Poor wound healing in diabetes mellitus may be related to perlecan expression. High levels of glucose can decrease perlecan expression in some cells probably through transcriptional and post-transcriptional modification. Wound healing phases especially, granulation, re-epithelization and remodeling exhibit controlled turnover of extracellular matrix components.
Diabetes mellitus is a metabolic disorder and hence the defects observed in diabetic wound healing are thought to be the result of altered protein and lipid metabolism and thereby abnormal granulation tissue formation. Increased glucose levels in the body end up in uncontrolled covalent bonding of aldose sugars to a protein or lipid without any normal glycosylation enzymes. These stable products then accumulate over the surface of cell membranes, structural proteins and circulating proteins. These products are called advanced glycation endproducts (AGEs) or Amadori products. Formation of AGEs occurs on extracellular matrix proteins with slow turnover rate. AGEs alter the properties of matrix proteins such as collagen, vitronectin, and laminin through AGE-AGE intermolecular covalent bonds or cross-linking. AGE cross-linking on type I collagen and elastin results in increased stiffness. AGEs are also known to increase synthesis of type III collagen that forms the granulation tissue. AGEs on laminin result in reduced binding to type IV collagen in the basement membrane, reduced polymer elongation and reduced binding of heparan sulfate proteoglycan.
- Impaired NO synthesis
Nitric oxide is known as an important stimulator of cell proliferation, maturation and differentiation. Thus, nitric oxide increases fibroblast proliferation and thereby collagen production in wound healing. Also, L-arginine and nitric oxide are required for proper cross linking of collagen fibers, via proline, to minimize scarring and maximize the tensile strength of healed tissue. Endothelial cell specific nitric oxide synthase (EcNOS) is activated by the pulsatile flow of blood through vessels. Nitric oxide produced by EcNOS, maintains the diameter of blood vessels and proper blood flow to tissues. In addition to this, nitric oxide also regulates angiogenesis, which plays a major role in wound healing. Thus, diabetic patients exhibit reduced ability to generate nitric oxide from L-arginine. Reasons that have been postulated in the literature include accumulation of nitric oxide synthase inhibitor due to high glucose associated kidney dysfunction and reduced production of nitric oxide synthase due to ketoacidosis observed in diabetic patients and pH dependent nature of nitric oxide synthase.
- Structural and functional changes in fibroblasts
Diabetic ulcer fibroblasts show various morphological differences compared to fibroblasts from age matched controls. Diabetic ulcer fibroblasts are usually large and widely spread in the culture flask compared to the spindle shaped morphology of the fibroblasts in age-matched controls. They often show dilated endoplasmic reticulum, numerous vesicular bodies and lack of microtubular structure in transmission electron microscopy study. Therefore, interpretation of these observations would be that in spite of high protein production and protein turnover in diabetic ulcer fibroblasts, vesicles containing secretory proteins could not travel along the microtubules to release the products outside. Fibroblasts from diabetic ulcer exhibit proliferative impairment that probably contributes to a decreased production of extracellular matrix proteins and delayed wound contraction and impaired wound healing.
- Increased matrix metalloproteinases (MMP) activity
In order for a wound to heal, extracellular matrix not only needs to be laid down but also must be able to undergo degradation and remodeling to form a mature tissue with appropriate tensile strength. Proteases, namely matrix metalloproteinases are known to degrade almost all the extracellular matrix components. They are known to be involved in fibroblast and keratinocyte migration, tissue re-organization, inflammation and remodeling of the wounded tissue. Due to persistently high concentrations of pro-inflammatory cytokines in diabetic ulcers, MMP activity is known to increase by 30 fold when compared to acute wound healing. MMP-2 and MMP-9 show sustained overexpression in chronic non-healing diabetic ulcers. Balance in the MMP activity is usually achieved by tissue inhibitor of metalloproteinases (TIMP). Rather than absolute concentrations of either two, it is the ratio of MMP and TIMP that maintains the proteolytic balance and this ratio is found to be disturbed in diabetic ulcer. In spite of these findings, the exact mechanism responsible for increased MMP activity in diabetes is not known yet. One possible line of thought considers Transforming growth factor beta (TGF-β) as an active player. Most MMP genes have TGF-β inhibitory element in their promoter regions and thus TGF–β regulates the expression of both MMP and their inhibitor TIMP. In addition to the importance of cell-cell and cell-matrix interactions, all phases of wound healing are controlled by a wide variety of different growth factors and cytokines. To mention precisely, growth factors promote switching of early inflammatory phase to the granulation tissue formation. Decrease in growth factors responsible for tissue repair such as TGF-β is documented in diabetic wounds. Thus, reduced levels of TGFβ in diabetes cases lower down the effect of inhibitory regulatory effect on MMP genes and thus cause MMPs to over express.
Complications in the diabetic foot and foot-ankle complex are wider and more destructive than expected, and may compromise structure and function of several systems: vascular, nervous, somatosensory, musculoskeletal. Thus, a deeper comprehension of the alteration of gait and foot biomechanics in the diabetic foot is of great interest, and may play a role in the design and onset of preventive as well as therapeutic actions.
Briefly, the effect of diabetes on the main structures of the foot-ankle complex can be summarised as:
- effects on skin: skin – and the soft tissues immediately underneath the skin – undergo greater compression and shear loading than usual, thus explaining the onset of tissue damage so deeply correlated to traumatic ulceration processes. Besides this, skin of the diabetic foot suffers from loss of autonomic nervous control and consequently reduced hydration, making it less elastic and thus more vulnerable to the action of increased mechanical stress;
- effects on tendons and ligaments: protein glycosylation and the resulting collagen abnormalities lead to greater transversal section – i.e. thickening – of tendons and ligaments and a greater coefficient of elasticity. Particularly impacted by this process are Plantar Fascia and Achilles Tendon. Both causes lead to an increased stiffness of those structures;
- effects on cartilage: similar to what happens to tendons and ligaments, cartilage changes its composition mainly due to the modification of collagen fibers. This increases its stiffness and decreases the range of motion of all joints in the foot and ankle.
- effects on muscles: Diabetes mellitus causes severe damage to nerve conduction, thus causing a worsening in the management of the related muscle fibers. As a consequence, both intrinsic and extrinsic muscles of the foot-ankle complex are damaged in structure (reduction of muscle volume) and function (reduction of muscle strength);
- effects on peripheral sensory system: impaired nerve conduction has a dramatic effect on the peripheral sensory system, since it leads to loss of protective sensation under the sole of the foot. This exposes the diabetic foot to thermal or mechanical trauma, and to the late detection of infection processes or tissue breakdown;
- effects on foot morphology (deformities): due to most of the above alterations, a significant imbalance of peripheral musculature and soft tissue occur in the foot which seriously alters its morphology and determines the onset of foot deformities. Most common deformities of the diabetic foot are represented by a high longitudinal arch (rigid cavus foot), hammer toes and hallux valgus. A completely different morphologic degeneration is represented by neuropathic arthropathy, whose analysis is not part of this discussion.
Assessment of diabetic foot ulcer includes identifying risk factors such as diabetic peripheral neuropathy, noting that 50 percent of people are asymptomatic, and ruling out other causes of peripheral neuropathy such as alcohol abuse and spinal injury.
The location of the ulcer, its size, shape, depth and whether the tissue is granulating or sloughy needs to be considered. Further considerations include whether there is malodour, condition of the border of the wound and palpable bone and sinus formation should be investigated. Signs of infection require to be considered such as development of grey or yellow tissue, purulent discharge, unpleasant smell, sinus, undermined edges and exposure of bone or tendon.
Identification of diabetic foot in medical databases, such as commercial claims and prescription data, is complicated by the lack of a specific ICD-9 code for diabetic foot and variation in coding practices. The following codes indicate ulcer of the lower limb or foot:
- 707.1 Ulcer of lower limbs, except pressure ulcer
- 707.14 Ulcer of heel and midfoot
- 707.15 Ulcer of other part of foot
- 707.19 Ulcer of other part of lower limb
One or more codes, in combination with a current or prior diagnosis of diabetes may be sufficient to conclude diabetic foot:
- 250.0 Diabetes Mellitus
- 250.8 Diabetes with other specified manifestations
- Foot-care education combined with increased surveillance can reduce the incidence of serious foot lesions.
The evidence for special footwear to prevent foot ulcers is poor.
Clinical Evidence reviewed the topic and concluded "Individuals with significant foot deformities should be considered for referral and assessment for customised shoes that can accommodate the altered foot anatomy. In the absence of significant deformities, high quality well fitting non-prescription footwear seems to be a reasonable option". National Institute for Health and Clinical Excellence concluded that for people at "high risk of foot ulcers (neuropathy or absent pulses plus deformity or skin changes or previous ulcer" that "specialist footwear and insoles" should be provided.
People with loss of feeling in their feet should inspect their feet on a daily basis, to ensure that there are no wounds starting to develop. They should not walk around barefoot, but use proper footwear at all times.
Foot ulcers in diabetes require multidisciplinary assessment, usually by diabetes nurse specialist, a tissue viability nurse, podiatrists, diabetes specialists and surgeons. An aim to improve glycaemic control, if poor, forms part of the management, to slow disease progression. Individuals who have sausage shaped toes, a positive 'probe to bone' test, evidence suggesting osteomyelitis, suspected charcot neuroarthropathy, or those whose ulcers do not improve within 4 weeks of standard care and where there is evidence that exudate is of synovial membrane in origin. When osteomyelitis is suspected to be involved in the foot ulcer, but not evidenced on an x-ray, an MRI scan should be obtained.
With regards to infected foot ulcers, the presence of microorganisms is not in itself enough to determine whether an infection is present. Signs such as inflammation and purulence are the best indicators of an active infection. The most common organism causing infection is staphylococcus. The treatment consists of debridement, appropriate bandages, managing peripheral arterial disease and appropriate use of antibiotics (against pseudomonas aeruginosa, staphylococcus, streptococcus and anaerobe strains), and arterial revascularisation.
The length of antibiotic courses depend on the severity of the infection and whether bone infection is involved but can range from 1 week to 6 weeks or more. Current recommendations are that antibiotics are only used when there is evidence of infection and continued until there is evidence that the infection has cleared, instead of evidence of ulcer healing. Choice of antibiotic depends on common local bacterial strains known to infect ulcers. Microbiological swabs are believed to be of limited value in identifying causative strain. Microbiological investigation is of value in cases of osteomyelitis. Most ulcer infections involve multiple microorganisms.
There are many types of dressings used to treat diabetic foot ulcers such as absorptive fillers, hydrogel dressings, and hydrocolloids. There is no good evidence that one type of dressing is better than another for diabetic foot ulcers. In selecting dressings for chronic non healing wounds it is recommended that the cost of the product be taken into account.
Hydrogel dressings may have shown a slight advantage over standard dressings, but the quality of the research is of concern. Dressings and creams containing silver have not been properly studied nor have alginate dressings. Biologically active bandages that combine hydrogel and hydrocolloid traits are available, however more research needs to be conducted as to the efficacy of this option over others.
Total contact castingEdit
Total contact casting (TCC) is a specially designed cast designed to take weight of the foot (off-loading) in patients with DFUs. Reducing pressure on the wound by taking weight of the foot has proven to be very effective in DFU treatment. DFUs are a major factor leading to lower leg amputations among the diabetic population in the US with 85% of amputations in diabetics being preceded by a DFU. Furthermore, the 5 year post-amputation mortality rate among diabetics is estimated at around 45% for those suffering from neuropathic DFUs.
TCC has been used for off-loading DFUs in the US since the mid-1960s and is regarded by many practitioners as the “reference standard” for off-loading the bottom surface (sole) of the foot.
TCC helps patients to maintain their quality of life. By encasing the patient’s complete foot — including the toes and lower leg — in a specialist cast to redistribute weight and pressure from the foot to the lower leg during everyday movements, patients can remain mobile. The manner in which TCC redistributes pressure protects the wound, letting damaged tissue regenerate and heal. TCC also keeps the ankle from rotating during walking, which helps prevent shearing and twisting forces that can further damage the wound.
Effective off loading is a key treatment modality for DFUs, particularly those where there is damage to the nerves in the feet (peripheral neuropathy). Along with infection management and vascular assessment, TCC is vital aspect to effectively managing DFUs. TCC is the most effective and reliable method for off-loading DFUs.
A 2013 meta-analysis by the Cochrane Collaboration compared the effectiveness of non-removable pressure relieving interventions, such as casts, with therapeutic shoes, dressings, removable pressure relieving orthotic devices, and surgical interventions. Non-removable pressure relieving interventions, including non-removable casts with an Achilles tendon lengthening component, were found to be more effective at healing foot ulcers related to diabetes that therapeutic shoes and other pressure relieving approaches.
In 2015, a Cochrane review concluded that for people with diabetic foot ulcers, hyperbaric oxygen therapy reduced the risk of amputation and may improve the healing at 6 weeks. However, there was no benefit at one year and the quality of the reviewed trials was inadequate to draw strong conclusions.
Negative pressure wound therapyEdit
This treatment uses vacuum to remove excess fluid and cellular waste that usually prolong the inflammatory phase of wound healing. Despite a straightforward mechanism of action, results of negative pressure wound therapy studies have been inconsistent. Research needs to be carried out to optimize the parameters of pressure intensity, treatment intervals and exact timing to start negative pressure therapy in the course of chronic wound healing.
Approximately 15 percent of people with diabetes experience foot ulcers. And approximately 84 percent of lower limb amputations have a history of ulceration with only approximately half of amputees surviving for more than 2 years. 56 percent of individuals with foot ulcers who do not have an amputations survive for 5 years. Foot ulcers and amputations significantly reduce the quality of life. Approximately 8.8 percent of hospital admissions of diabetic patients are for foot related problems, and such hospital admissions are about 13 days longer than for diabetics without foot related admissions. Approximately 35 to 40 percent of ulcers recur within 3 years and up to 70 percent recur within 5 years. Diabetic foot disease is the leading cause of non-traumatic lower limb amputations.
Stem cell therapy may represent a treatment for promoting healing of diabetic foot ulcers. Diabetic foot ulcers develop their own, distinctive microbiota. Investigations into characterizing and identifying the phyla, genera and species of nonpathogenic bacteria or other microorganisms populating these ulcers may help identify one group of microbiota that promotes healing.
The recent advances in epigenetic modifications, with special focus on aberrant macrophage polarisation is giving increasing evidences that epigenetic modifications might play a vital role in changing the treatment of diabetic foot ulcer in the near future.
- Nomikos Iakovos N; et al. (2006). "Protective and Damaging Aspects of Healing: A Review". Wounds. 18 (7): 177–185.
- McLennan S; et al. (2006). ", Molecular aspects of wound healing" (PDF). Primary intention. 14 (1): 8–13.
- Yazdanpanah, L; Nasiri, M; Adarvishi, S (15 February 2015). "Literature review on the management of diabetic foot ulcer". World journal of diabetes. 6 (1): 37–53. doi:10.4239/wjd.v6.i1.37. PMC . PMID 25685277.
- Brem, H.; Tomic-Canic, M. (2007). "Cellular and molecular basis of wound healing in diabetes". Journal of Clinical Investigation. 117 (5): 1219–1222. doi:10.1172/JCI32169. PMC . PMID 17476353.
- Turns M (2013). "Diabetic foot ulcer management: the podiatrist's perspective". Br J Community Nurs. Suppl: S14, S16–9. PMID 24796080.
- Turns M (2011). "The diabetic foot: an overview of assessment and complications". Br J Nurs. 20 (15): S19–25. doi:10.12968/bjon.2011.20.Sup8.S19. PMID 21841646.
- Hamilton, Rob and Julie. "Diabetic Ulcers: Everything You Need to Know". Healing Your Wound. Retrieved September 6, 2018.
- Turns M (2012). "The diabetic foot: an overview for community nurses". Br J Community Nurs. 17 (9): 422, 424–27, 430–3. doi:10.12968/bjcn.2012.17.9.422. PMID 23123487.
- Scott, G (March–April 2013). "The diabetic foot examination: A positive step in the prevention of diabetic foot ulcers and amputation". Osteopathic Family Physician. 5 (2): 73–78. doi:10.1016/j.osfp.2012.08.002.
- Wu, S. C.; Driver, V. R.; Wrobel, J. S.; Armstrong, D. G. (2007). "Foot ulcers in the diabetic patient, prevention and treatment". Vascular health and risk management. 3 (1): 65–76. PMC . PMID 17583176.
- Hay Elizabeth (1991). Cell biology of extracellular matrix second edition. New York: Plenum press. pp. 1–5. ISBN 0-306-40785-X.
- Sweitzer, S. M.; Fann, S. A.; Borg, T. K.; Baynes, J. W.; Yost, M. J. (2006). "What is the Future of Diabetic Wound Care?". The Diabetes Educator. 32 (2): 197–210. doi:10.1177/0145721706286897. PMID 16554422.
- Schultz GS, Ludwig G, Wysocki A. Extracellular matrix: review of its roles in acute and chronic wounds. World Wide Wounds 2005. http://www.worldwidewounds.com/2005/august/Schultz/Extrace-Matric-Acute-Chronic-Wounds.html
- Carrie Sussman (2006). Wound Care:a collaborative practice manual third Edition. Lippincott Williams & Wilkins. pp. 21–47. ISBN 978-0-7817-7444-4.
- Thomas, D. W.; O'Neill, I. D.; Harding, K. G.; Shepherd, J. P. (1995). "Cutaneous wound healing: A current perspective". Journal of Oral and Maxillofacial Surgery. 53 (4): 442–447. doi:10.1016/0278-2391(95)90721-1. PMID 7699500.
- Loots, M. A. M.; Lamme, E. N.; Zeegelaar, J.; Mekkes, J. R.; Bos, J. D.; Middelkoop, E. (1998). "Differences in Cellular Infiltrate and Extracellular Matrix of Chronic Diabetic and Venous Ulcers Versus Acute Wounds". Journal of Investigative Dermatology. 111 (5): 850–857. doi:10.1046/j.1523-1747.1998.00381.x. PMID 9804349.
- Decarlo, Arthur A et al, 'Wound and cutaneous injury healing with a nucleic acid encoding perlecan’, United States Patent 7141551, Nov.2006
- Janet Close-Tweedie, "Daibetic foot wounds and wound healing: a review, The Diabetic Foot 2002; 68
- Goldin, A.; Beckman, J. A.; Schmidt, A. M.; Creager, M. A. (2006). "Advanced Glycation End Products: Sparking the Development of Diabetic Vascular Injury". Circulation. 114 (6): 597–605. doi:10.1161/CIRCULATIONAHA.106.621854. PMID 16894049.
- Singh R, et al. (2001). "Advanced glycation end-products: a review". Diabetologia. 44: 129–146. doi:10.1007/s001250051591.
- Brownlee, M. D. (1995). "Advanced Protein Glycosylation in Diabetes and Aging". Annual Review of Medicine. 46: 223–234. doi:10.1146/annurev.med.46.1.223. PMID 7598459.
- Obayashi, K.; Akamatsu, H.; Okano, Y.; Matsunaga, K.; Masaki, H. (2006). "Exogenous nitric oxide enhances the synthesis of type I collagen and heat shock protein 47 by normal human dermal fibroblasts". Journal of Dermatological Science. 41 (2): 121–126. doi:10.1016/j.jdermsci.2005.08.004. PMID 16171977.
- Duda, D. G.; Fukumura, D.; Jain, R. K. (2004). "Role of eNOS in neovascularization: NO for endothelial progenitor cells". Trends in Molecular Medicine. 10 (4): 143–145. doi:10.1016/j.molmed.2004.02.001. PMID 15162796.
- Linden, E.; Cai, W.; He, J. C.; Xue, C.; Li, Z.; Winston, J.; Vlassara, H.; Uribarri, J. (2008). "Endothelial Dysfunction in Patients with Chronic Kidney Disease Results from Advanced Glycation End Products (AGE)-Mediated Inhibition of Endothelial Nitric Oxide Synthase through RAGE Activation". Clinical Journal of the American Society of Nephrology. 3 (3): 691–698. doi:10.2215/CJN.04291007. PMC . PMID 18256374.
- Loots, M. A.; Lamme, E. N.; Mekkes, J. R.; Bos, J. D.; Middelkoop, E. (1999). "Cultured fibroblasts from chronic diabetic wounds on the lower extremity (non-insulin-dependent diabetes mellitus) show disturbed proliferation". Archives of dermatological research. 291 (2–3): 93–99. doi:10.1007/s004030050389. PMID 10195396.
- Rowe, D. W.; Starman, B. J.; Fujimoto, W. Y.; Williams, R. H. (1977). "Abnormalities in proliferation and protein synthesis in skin fibroblast cultures from patients with diabetes mellitus". Diabetes. 26 (4): 284–290. doi:10.2337/diabetes.26.4.284. PMID 849809.
- Ravanti, L.; Kähäri, V. M. (2000). "Matrix metalloproteinases in wound repair (review)". International journal of molecular medicine. 6 (4): 391–407. doi:10.3892/ijmm.6.4.391. PMID 10998429.
- Vaalamo, M.; Leivo, T.; Saarialho-Kere, U. (1999). "Differential expression of tissue inhibitors of metalloproteinases (TIMP-1, −2, −3, and −4) in normal and aberrant wound healing". Human pathology. 30 (7): 795–802. doi:10.1016/s0046-8177(99)90140-5. PMID 10414498.
- Wysocki, A. B.; Staiano-Coico, L.; Grinnell, F. (1993). "Wound fluid from chronic leg ulcers contains elevated levels of metalloproteinases MMP-2 and MMP-9". The Journal of Investigative Dermatology. 101 (1): 64–68. doi:10.1111/1523-1747.ep12359590. PMID 8392530.
- Lobmann, R.; Ambrosch, A.; Schultz, G.; Waldmann, K.; Schiweck, S.; Lehnert, H. (2002). "Expression of matrix-metalloproteinases and their inhibitors in the wounds of diabetic and non-diabetic patients". Diabetologia. 45 (7): 1011–1016. doi:10.1007/s00125-002-0868-8. PMID 12136400.
- Muller, M.; Trocme, C.; Lardy, B.; Morel, F.; Halimi, S.; Benhamou, P. Y. (2008). "Matrix metalloproteinases and diabetic foot ulcers: The ratio of MMP-1 to TIMP-1 is a predictor of wound healing". Diabetic Medicine. 25 (4): 419–426. doi:10.1111/j.1464-5491.2008.02414.x. PMC . PMID 18387077.
- McLennan, S. V.; Fisher, E.; Martell, S. Y.; Death, A. K.; Williams, P. F.; Lyons, J. G.; Yue, D. K. (2000). "Effects of glucose on matrix metalloproteinase and plasmin activities in mesangial cells: Possible role in diabetic nephropathy". Kidney International Supplement. 77: S81–S87. PMID 10997695.
- Bennett, N. T.; Schultz, G. S. (1993). "Growth factors and wound healing: Part II. Role in normal and chronic wound healing". American journal of surgery. 166 (1): 74–81. doi:10.1016/s0002-9610(05)80589-6. PMID 8392302.
- Galkowska, H.; Wojewodzka, U.; Olszewski, W. L. (2006). "Chemokines, cytokines, and growth factors in keratinocytes and dermal endothelial cells in the margin of chronic diabetic foot ulcers". Wound Repair and Regeneration. 14 (5): 558–565. doi:10.1111/j.1743-6109.2006.00155.x. PMID 17014667.
- Vileikyte L, Rubin RR, Peyrot M, Gonzalez JS, Boulton AJ, Ulbrecht JS, Cavanagh PR. Diabetic feet. Br J Gen Pract. 2009 Apr;59(561) 290. 14
- Jeffcoate WJ, Lipsky BA, Berendt AR, Cavanagh PR, Bus SA, Peters EJ, van Houtum WH, Valk GD, Bakker K, et al. (Dec 2008). "Unresolved issues in the management of ulcers of the foot in diabetes". Diabet. Med. 25 (12): 1380–9. doi:10.1111/j.1464-5491.2008.02573.x.
- Bus, S. A.; Valk, G. D.; Van Deursen, R. W.; Armstrong, D. G.; Caravaggi, C.; Hlaváček, P.; Bakker, K.; Cavanagh, P. R. (2008). "Specific guidelines on footwear and offloading". Diabetes/Metabolism Research and Reviews. 24: S192–S193. doi:10.1002/dmrr.855. PMID 18442186.
- Bus, S. A.; Valk, G. D.; Van Deursen, R. W.; Armstrong, D. G.; Caravaggi, C.; Hlaváček, P.; Bakker, K.; Cavanagh, P. R. (2008). "The effectiveness of footwear and offloading interventions to prevent and heal foot ulcers and reduce plantar pressure in diabetes: A systematic review". Diabetes/Metabolism Research and Reviews. 24: S162–S180. doi:10.1002/dmrr.850. PMID 18442178.
- Ledoux W. The Biomechanics of the Diabetic Foot (chapter 20, pages 317–401). In: Foot And Ankle Motion Analysis (Clinical Treatment and Technology), Eds G.F. Harris, P.A. Smith, R. M. Marks, CRC Press, USA, 2008, ISBN 0-8493-3971-5
- Litzelman, D. K.; Slemenda, C. W.; Langefeld, C. D.; Hays, L. M.; Welch, M. A.; Bild, D. E.; Ford, E. S.; Vinicor, F. (1993). "Reduction of lower extremity clinical abnormalities in patients with non-insulin-dependent diabetes mellitus. A randomized, controlled trial". Annals of Internal Medicine. 119 (1): 36–41. doi:10.7326/0003-4819-119-1-199307010-00006. PMID 8498761.
- Hunt, D. (2005). "Foot ulcers and amputations in diabetes". Clinical evidence (14): 455–462. PMID 16620415.
- "Scope: Management of type 2 diabetes: prevention and management of foot problems (update)" (PDF). Clinical Guidelines and Evidence Review for Type 2 Diabetes: Prevention and Management of Foot Problems. National Institute for Health and Clinical Excellence. 20 February 2003. Retrieved 2007-12-04.
- Hilton, J.R.; D.T. Williams; B. Beuker; D.R. Miller; K.G. Harding (2004). "Wound Dressings in Diabetic Foot Disease". Clinical Infectious Diseases. 39 (Supplement 2): S100–S103. doi:10.1086/383270.
- Wu, L; Norman, G; Dumville, JC; O'Meara, S; Bell-Syer, SE (14 July 2015). "Dressings for treating foot ulcers in people with diabetes: an overview of systematic reviews". The Cochrane Database of Systematic Reviews. 7: CD010471. doi:10.1002/14651858.CD010471.pub2. PMID 26171906.
- Dumville, JC; Deshpande, S; O'Meara, S; Speak, K (6 June 2013). "Foam dressings for healing diabetic foot ulcers". The Cochrane Database of Systematic Reviews. 6: CD009111. doi:10.1002/14651858.CD009111.pub3. PMID 23740766.
- Dumville, JC; O'Meara, S; Deshpande, S; Speak, K (12 July 2013). "Hydrogel dressings for healing diabetic foot ulcers". The Cochrane Database of Systematic Reviews. 7: CD009101. doi:10.1002/14651858.CD009101.pub3. PMID 23846869.
- Bergin, SM; Wraight, P (Jan 25, 2006). "Silver based wound dressings and topical agents for treating diabetic foot ulcers". Cochrane Database of Systematic Reviews (1): CD005082. doi:10.1002/14651858.CD005082.pub2. PMID 16437516.
- Dumville, JC; O'Meara, S; Deshpande, S; Speak, K (25 June 2013). "Alginate dressings for healing diabetic foot ulcers". The Cochrane Database of Systematic Reviews. 6: CD009110. doi:10.1002/14651858.CD009110.pub3. PMID 23799857.
- Incidence of diabetic foot ulcer and lower extremity amputation among Medicare beneficiaries, 2006 to 2008, www.ahrq.gov.
- Armstrong D.G.; et al. (2004). "It's not what you put on, but what you take off: techniques for debriding and off-loading the diabetic foot wound". Clin Infect Dis. 39 (Suppl 2): S92–9. doi:10.1086/383269.
- Farid K, Farid M, Andrews CM (2008). "Total contact casting as part of an adaptive care approach: a case study". Ostomy Wound Manage. 54 (6): 50–65.
- Raspovic, A. and K.B. Landorf, A survey of offloading practices for diabetes-related plantar neuropathic foot ulcers. J Foot Ankle Res, 2014. 7: p. 35.
- Snyder R.J.; et al. (2014). "The management of diabetic foot ulcers through optimal off-loading building consensus guidelines and practical recommendations to improve outcomes". J Am Podiatr Med Assoc. 104 (6): 555–67. doi:10.7547/8750-7315-104.6.555.
- Armstrong, D.G., et al., Off-loading the diabetic foot wound: a randomized clinical trial. Diabetes Care, 2001. 24(6): p. 1019-22.
- Lavery L.A.; et al. (1996). ""Reducing dynamic foot pressures in high-risk diabetic subjects with foot ulcerations " a comparison of treatments". Diabetes Care. 19: 818–821. doi:10.2337/diacare.19.8.818.
- Lewis, J. and A. Lipp, "Pressure-relieving interventions for treating diabetic foot ulcers. Cochrane Database Syst Rev, 2013; 1: p. Cd002302.
- Spencer, S. (2000-01-01). "Pressure relieving interventions for preventing and treating diabetic foot ulcers". The Cochrane Database of Systematic Reviews (3): CD002302. doi:10.1002/14651858.CD002302. ISSN 1469-493X. PMID 10908550.
- Kranke, Peter; Bennett, Michael H.; Martyn-St James, Marrissa; Schnabel, Alexander; Debus, Sebastian E.; Weibel, Stephanie (2015-06-24). "Hyperbaric oxygen therapy for chronic wounds". The Cochrane Database of Systematic Reviews (6): CD004123. doi:10.1002/14651858.CD004123.pub4. ISSN 1469-493X. PMID 26106870.
- Armstrong, D. G.; Lavery, L. A.; Abu-Rumman, P.; Espensen, E. H.; Vazquez, J. R.; Nixon, B. P.; Boulton, A. J. (2002). "Outcomes of subatmospheric pressure dressing therapy on wounds of the diabetic foot". Ostomy/wound management. 48 (4): 64–68. PMID 11993062.
- Liu J, Zhang P, Tian J, Li L, Li J, Tian JH, Yang K (27 October 2015). "Ozone therapy for treating foot ulcers in people with diabetes". Cochrane Database of Systematic Reviews. 10: CD008474. doi:10.1002/14651858.CD008474.pub2. PMID 26505864.
- Martí-Carvajal AJ, Gluud C, Nicola S, Simancas-Racines D, Reveiz L, Oliva P, Cedeño-Taborda J (28 October 2015). "Growth factors for treating diabetic foot ulcers". Cochrane Database of Systematic Reviews. 10: CD008548. doi:10.1002/14651858.CD008548.pub2. PMID 26509249.
- Blumberg, SN; Berger, A; Hwang, L; Pastar, I; Warren, SM; Chen, W (April 2012). "The role of stem cells in the treatment of diabetic foot ulcers". Diabetes research and clinical practice. 96 (1): 1–9. doi:10.1016/j.diabres.2011.10.032. PMID 22142631.
- O’Loughlin, Aonghus. "Topical stem and progenitor cell therapy for diabetic foot ulcers". Ali Gholamrezanezhad (Ed.). doi:10.5772/19070.
- Di Rocco, G; Gentile, A; Antonini, A; Ceradini, F; Wu, JC; Capogrossi, MC; Toietta, G (Dec 26, 2010). "Enhanced healing of diabetic wounds by topical administration of adipose tissue-derived stromal cells overexpressing stromal-derived factor-1: biodistribution and engraftment analysis by bioluminescent imaging". Stem Cells International. 2011: 304562. doi:10.4061/2011/304562. PMC . PMID 21234108.
- Lavigne, Jean-Philippe; Sotto, Albert; Dunyach-Remy, Catherine; Lipsky, Benjamin A. (2015). "New Molecular Techniques to Study the Skin Microbiota of Diabetic Foot Ulcers". Advances in Wound Care. 4 (1): 38–49. doi:10.1089/wound.2014.0532. ISSN 2162-1918. PMC . PMID 25566413.
- Mallik SB, Jayashree BS, Shenoy RR. Epigenetic modulation of macrophage polarization-perspectives in diabetic wounds. Journal of diabetes and its complications. 2018 Feb 7.